Deal of the Day — limited-time pharmacy picks!
Imbruvica 140mg Capsule

Imbruvica 140mg Capsule

Prescription requiredRx Required

Salt Composition: Ibrutinib

Expiry Date: 01/2028

Special offer

Buy at $4,226.59

$4,226.59

Inclusive of all taxes

▼

90 capsules

About The Product

​Chronic lymphocytic leukemia, lymphocytic lymphoma​

Imbruvica 140mg Capsule is classified as an anticancer medication. Mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia, small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL), and marginal zone lymphoma (MZL) are among the blood cancers that are mainly treated with this medication.

In the human body, cancer cell development is uncontrolled and abnormal. Early cancer diagnosis is a challenging task. Only the disease's symptoms can be reduced when it is discovered in its advanced stages. Ibrutinib is the active ingredient in Imbruvica 140mg Capsule.

Uses

  • The Imbruvica 140 mg uses include: To treat mantle cell lymphoma
  • In the treatment of chronic lymphocytic leukaemia (Blood cancer) to treat small lymphocytic lymphoma
  • In the treatment of Waldenstrom’s macroglobulinemia
  • To treat chronic graft vs. host disease after failure of systemic therapy

Side Effects

The human body shows undesired symptoms after taking Imburuvica 140mg Tablet. Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention. It is advised to consult your doctor if these symptoms become unmanageable.
Some of the common side effects of Imburuvica Tablet are mentioned below:

  • High risk of infection
  • Vomiting
  • Weakness
  • Nausea
  • Fatigue
  • Fever
  • Decreased blood cells (red cells, white cells, and platelets), Diarrhea cough

How To Use

  • Imburuvica 140mg Tablet is a prescription-based anticancer drug.
  • It is advised to take this tablet after consulting your healthcare expert.
  • This medicine should be taken at the same time every day for better results.

How It Works

An inhibitor of Bruton's tyrosine kinase is imbruvica 140mg capsule. Inhibiting BTK signaling delays the onset of the disease, inhibits the cancer cells, and encourages apoptosis, or programmed cell death.

This focused strategy lowers the burden of tumors, enhances overall survival rates, and improves patient outcomes.

When taken orally, imbruvica offers long-term, sustained disease control and is a safer option than normal chemotherapy.


Safety Advice

Alcohol

The interaction of alcohol with this drug is still unknown. It is advisable not to consume alcohol while taking Imburuvica 140mg Tablet. It is advised to consult your doctor for further information.

Pregnancy

Imburuvica 140mg Tablet may be considered unsafe during pregnancy. Please consult your doctor in such condition.

Breast Feeding

Imburuvica 140mg Tablet is probably not safe if you're breastfeeding. Kindly consult your doctor.

Driving

It is advisable not to drive or operate heavy machinery as you may feel dizzy after taking Imburuvica 140mg Tablet.

Kidney

Share your medical history with your healthcare expert in case of kidney disease before taking Imburuvica 140mg Tablet.

Liver

Inform your doctor before starting Imburuvica 140mg Tablet if you have liver disease to avoid any serious side effects.

Missed Doses

  • It is advised not to miss any scheduled dosage of Imburuvica 140mg Tablet.
  • In case you miss a dose, consult your doctor immediately.
  • Don't overdose to compensate for the missed one.
  • Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.

FAQs

No, children below 18 years of age are not advised to take this medicine as it results in severe complications.

Reference

Chen, L.S et al., (2018). A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.

Blood, 132(21), 2249–2259 - https://pubmed.ncbi.nlm.nih.gov/30254130/ Davids, M. S., & Brown, J.

R. (2024).

Ibrutinib: A first-in-class covalent inhibitor of Bruton’s tyrosine kinase. Future Oncology, 10(6), 957–967.

Bioequivalence study of Binap® (ibrutinib 140 mg) vs. Imbruvica®.

(2024). Journal of Hematology - https://pubmed.ncbi.nlm.nih.gov/24941982/ Janssen Research & Development, LLC.

(2024). Study to assess the bioequivalence of ibrutinib 140 mg tablet to 140 mg IMBRUVICA capsule (NCT02877225).

ClinicalTrials.go - https://clinicaltrials.gov/study/NCT02877225 Li, S., Young, K. H., & Medeiros, L.

J. (2024). [Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL].

Blood Advances, 8(4), 832–841 - https://pmc.ncbi.nlm.nih.gov/articles/PMC10874751/ Ryan, C. (2025).

FDA approves generic ibrutinib tablets for B‑cell malignancies. OncLive - https://www.onclive.com/view/fda-approves-generic-ibrutinib-tablets-for-b-cell-malignancies

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026